Skip to main content
NAK
NYSE Energy & Transportation

Northern Dynasty Corrects Disclosure: Director Balakrishnan Had Five Cease-Trade Orders and a Bankruptcy Omission

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Energy
Sentiment info
Negative
Importance info
7
Price
$0.55
Mkt Cap
$320.311M
52W Low
$0.51
52W High
$2.66
52W Position info
7.9% above low
Off High info
79% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

NAK is trading near its 52-week low of $0.51 (7.9% above the low).

Summary

Northern Dynasty amended its November 17 6-K to correct prior disclosure, revealing that director Desmond Balakrishnan was on the boards of five companies hit with BCSC cease trade orders and of Hempfusion Wellness when it assigned into bankruptcy — omissions the 2025 AIF and 2026 circular never disclosed. Balakrishnan, whom the Board asked to resign, is staying.


Key Events · Executive and Board Changes · NAK

  • Board Wants Director Out, He Refuses

    The Governance Committee will not re-nominate Desmond Balakrishnan at the 2027 AGM, and the Board requested his resignation; he has determined not to resign and remains a director.

  • Five Undisclosed Cease Trade Orders

    The 2025 AIF and 2026 circular omitted BCSC cease trade orders issued while Balakrishnan was a director of Aroway Energy, Hempfusion Wellness, Isracann Biosciences, Cognetivity Neurosciences and Eat Well Investment Group; several remain in effect.

  • Undisclosed Bankruptcy Assignment

    Hempfusion Wellness Inc. made an assignment in bankruptcy on June 21, 2023, with FTI Consulting Canada Inc. as trustee; Balakrishnan was a director at the time, and the 2024 and 2025 circulars and AIFs never disclosed it.

  • Prior AIF Statement Corrected

    The 2025 AIF's statement that no director had been subject to a bankruptcy, cease trade order, penalty or sanction in the prior ten years was incorrect as to Balakrishnan and is corrected by this release.


Analysis · NAK · Energy & Transportation

The governance fight was already public: the committee won't re-nominate Desmond Balakrishnan, the Board asked him to resign, and he refused. What is new is why the story got worse. The company's 2025 AIF and 2026 circular failed to disclose that Balakrishnan sat on the boards of five issuers when BCSC cease trade orders were issued, and that Hempfusion Wellness made a bankruptcy assignment in June 2023 while he was a director. The AIF's blanket statement that no director had been subject to a cease trade order or bankruptcy in ten years was simply wrong. That is a disclosure-control failure at a company whose only asset is a permitting-stage mine, and it lands days after a Q3 profit that was entirely a non-cash convertible-note remeasurement gain. A director who won't leave after a failed withhold vote, plus corrected filings, is a governance overhang rather than an operating event.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, NAK was trading at $0.55 on NYSE in the Energy & Transportation sector, with a market capitalization of approximately $320.3M. The 52-week trading range was $0.51 to $2.66. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

NAK - Latest Insights

NAK
Nov 17, 2026, 12:10 PM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $0.57365
Real-time Price: $0.5504 info
Change: -$0.02325 (-4%) info
Market Cap: $320.311M info
NAK
Nov 16, 2026, 7:50 PM EST
Filing Type: 6-K
Importance Score:
8
Price at Filing: $0.5501
Real-time Price: $0.5504 info
Change: +$0.0003 (+0.05%) info
Market Cap: $320.311M info